Genomic similarity between gastroesophageal junction and esophageal Barrett's adenocarcinomas

The current high mortality rate of esophageal adenocarcinoma (EAC) reflects frequent presentation at an advanced stage. Recent efforts utilizing fluorescent peptides have identified overexpressed cell surface targets for endoscopic detection of early stage Barrett's-derived EAC. Unfortunately, 30% of EAC patients present with gastroesophageal junction adenocarcinomas (GEJAC) and lack premalignant Barrett's metaplasia, limiting this early detection strategy. We compared mRNA profiles from 52 EACs (tubular EAC; tEAC) collected above the gastroesophageal junction with 70 GEJACs, 8 normal esophageal and 5 normal gastric mucosa samples. We also analyzed our previously published whole-exome sequencing data in a large cohort of these tumors. Principal component analysis, hierarchical clustering and survival-based analyses demonstrated that GEJAC and tEAC were highly similar, with only modest differences in expression and mutation profiles. The combined expression cohort allowed identification of 49 genes coding cell surface targets overexpressed in both GEJAC and tEAC. We confirmed that three of these candidates (CDH11, ICAM1 and CLDN3) were overexpressed in tumors when compared to normal esophagus, normal gastric and non-dysplastic Barrett's, and localized to the surface of tumor cells. Molecular profiling of tEAC and GEJAC tumors indicated extensive similarity and related molecular processes. Identified genes that encode cell surface proteins overexpressed in both Barrett's-derived EAC and those that arise without Barrett's metaplasia will allow simultaneous detection strategies.

[1]  M. van Ballegooijen,et al.  The Impact of Uncertainty in Barrett’s Esophagus Progression Rates on Hypothetical Screening and Treatment Decisions , 2015, Medical decision making : an international journal of the Society for Medical Decision Making.

[2]  Marian Hajduch,et al.  Diagnostic and prognostic potential of miR-21, miR-29c, miR-148 and miR-203 in adenocarcinoma and squamous cell carcinoma of esophagus , 2015, Diagnostic Pathology.

[3]  Kevin A. Henry,et al.  Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State , 2015, Journal of the National Cancer Institute.

[4]  L. Du,et al.  MiR-203 Suppresses ZNF217 Upregulation in Colorectal Cancer and Its Oncogenicity , 2015, PloS one.

[5]  Peter J. Campbell,et al.  Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis , 2014, Nature Communications.

[6]  M. Esteller,et al.  A comprehensive DNA methylation profile of epithelial-to-mesenchymal transition. , 2014, Cancer research.

[7]  Fredrik Mattsson,et al.  Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Wenjin Xi,et al.  MiR‐200c suppresses TGF‐β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer , 2014, International journal of cancer.

[9]  F. Vleggaar,et al.  Surveillance of Barrett's Esophagus and Mortality from Esophageal Adenocarcinoma: A Population-Based Cohort Study , 2014, The American Journal of Gastroenterology.

[10]  P. Farnham,et al.  Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha , 2014, BMC Genomics.

[11]  Thomas D. Wang,et al.  TGM2: A Cell Surface Marker in Esophageal Adenocarcinomas , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  R. Langer,et al.  Multi-colour FISH in oesophageal adenocarcinoma—predictors of prognosis independent of stage and grade , 2014, British Journal of Cancer.

[13]  N. Hayward,et al.  Genome‐wide analysis of esophageal adenocarcinoma yields specific copy number aberrations that correlate with prognosis , 2014, Genes, chromosomes & cancer.

[14]  Christian Stolte,et al.  COMPARTMENTS: unification and visualization of protein subcellular localization evidence , 2014, Database J. Biol. Databases Curation.

[15]  J. Byrne,et al.  The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction , 2013, Journal of surgical oncology.

[16]  J. Ajani,et al.  Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Hagen,et al.  Effect of Barrett's esophagus surveillance on esophageal preservation, tumor stage, and survival with esophageal adenocarcinoma. , 2013, The Journal of thoracic and cardiovascular surgery.

[18]  Thomas D. Wang,et al.  Targeted Imaging of Esophageal Neoplasia with a Fluorescently Labeled Peptide: First-in-Human Results , 2013, Science Translational Medicine.

[19]  A. McKenna,et al.  Exome and whole genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity , 2013, Nature Genetics.

[20]  L. Mccauley,et al.  Signaling between Transforming Growth Factor β (TGF-β) and Transcription Factor SNAI2 Represses Expression of MicroRNA miR-203 to Promote Epithelial-Mesenchymal Transition and Tumor Metastasis* , 2013, The Journal of Biological Chemistry.

[21]  F. Khuri,et al.  Risk Factors for Rising Incidence of Esophageal and Gastric Cardia Adenocarcinoma , 2013, Journal of Gastrointestinal Cancer.

[22]  E. Kremmer,et al.  Identification of ZNF217, hnRNP‐K, VEGF‐A and IPO7 as targets for microRNAs that are downregulated in prostate carcinoma , 2013, International journal of cancer.

[23]  T. Vaughan,et al.  Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. , 2013, Seminars in radiation oncology.

[24]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[25]  A. Thrift,et al.  The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Howard Y. Chang,et al.  The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. , 2012, Cancer discovery.

[27]  Jian Ye,et al.  Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction , 2012, BMC Bioinformatics.

[28]  S. Wijetunge,et al.  Changing trend of oesophageal adenocarcinoma and cardia carcinoma incidence; review of literature and analysis , 2012 .

[29]  I. Bièche,et al.  ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion. , 2012, Cancer research.

[30]  M. Meyerson,et al.  Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma , 2012, Proceedings of the National Academy of Sciences.

[31]  Thomas D. Wang,et al.  Targeted detection of murine colonic dysplasia in vivo with flexible multispectral scanning fiber endoscopy. , 2012, Journal of biomedical optics.

[32]  Rebecca C Fitzgerald,et al.  Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus , 2012, Nature Medicine.

[33]  S. Anandasabapathy,et al.  Pre-Clinical Evaluation of Fluorescent Deoxyglucose as a Topical Contrast Agent for the Detection of Barrett’s-Associated Neoplasia during Confocal Imaging , 2011, Technology in cancer research & treatment.

[34]  Z. Fang,et al.  Coexistence of copy number increases of ZNF217 and CYP24A1 in colorectal cancers in a Chinese population. , 2010, Oncology letters.

[35]  Kenneth K Wang,et al.  Genome-Wide Catalogue of Chromosomal Aberrations in Barrett's Esophagus and Esophageal Adenocarcinoma: A High-Density Single Nucleotide Polymorphism Array Analysis , 2010, Cancer Prevention Research.

[36]  Å. Borg,et al.  Genetic profiles of gastroesophageal cancer: combined analysis using expression array and tiling array--comparative genomic hybridization. , 2010, Cancer genetics and cytogenetics.

[37]  A. Tsykin,et al.  MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma , 2010, The British journal of surgery.

[38]  D. Beer,et al.  Decreased Selenium-Binding Protein 1 in Esophageal Adenocarcinoma Results from Posttranscriptional and Epigenetic Regulation and Affects Chemosensitivity , 2010, Clinical Cancer Research.

[39]  B. Reid,et al.  Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis , 2010, Nature Reviews Cancer.

[40]  P. Pauwels,et al.  Expression of hexokinases and glucose transporters in treated and untreated oesophageal adenocarcinoma. , 2009, Histology and histopathology.

[41]  M. Walsh,et al.  The ZNF217 oncogene is a candidate organizer of repressive histone modifiers , 2009, Epigenetics.

[42]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[43]  A. Corradin,et al.  DNA copy number alterations correlate with survival of esophageal adenocarcinoma patients , 2009, Modern Pathology.

[44]  N. Hayward,et al.  Genome-wide copy number analysis in esophageal adenocarcinoma using high-density single-nucleotide polymorphism arrays. , 2008, Cancer research.

[45]  Kenneth K Wang,et al.  Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus , 1998, The American Journal of Gastroenterology.

[46]  G. Cooper,et al.  Descriptive epidemiology of esophageal carcinoma in the Ohio Cancer Registry. , 2008, Cancer detection and prevention.

[47]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[48]  E. Montgomery,et al.  Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma , 2007, International journal of cancer.

[49]  Brad T. Sherman,et al.  The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists , 2007, Genome Biology.

[50]  M. Orringer,et al.  Two Thousand Transhiatal Esophagectomies: Changing Trends, Lessons Learned , 2007, Annals of surgery.

[51]  P. Yaswen,et al.  Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad. , 2007, Biochimica et biophysica acta.

[52]  J. Torchia,et al.  Biochemical characterization of the zinc-finger protein 217 transcriptional repressor complex: identification of a ZNF217 consensus recognition sequence , 2007, Oncogene.

[53]  Daniel Birnbaum,et al.  Prognosis and Gene Expression Profiling of 20q13-Amplified Breast Cancers , 2006, Clinical Cancer Research.

[54]  M. Feith,et al.  Biologic and clinical variations of adenocarcinoma at the esophago–gastric junction: Relevance of a topographic‐anatomic subclassification , 2005, Journal of surgical oncology.

[55]  B. Tilton,et al.  Housekeeping gene variability in normal and cancerous colorectal, pancreatic, esophageal, gastric and hepatic tissues. , 2005, Molecular and cellular probes.

[56]  Alok J. Saldanha,et al.  Java Treeview - extensible visualization of microarray data , 2004, Bioinform..

[57]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[58]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[59]  M. Feith,et al.  Preoperative chemotherapy unmasks underlying Barrett’s mucosa in patients with adenocarcinoma of the distal esophagus , 2002, Surgical Endoscopy.

[60]  M. Feith,et al.  Adenocarcinoma of the Esophagogastric Junction: Results of Surgical Therapy Based on Anatomical/Topographic Classification in 1,002 Consecutive Patients , 2000, Annals of surgery.

[61]  M. Omary,et al.  Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. , 2000, Gastroenterology.

[62]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[63]  J. Peters,et al.  Is Barrett's metaplasia the source of adenocarcinomas of the cardia? , 1994, Archives of surgery.

[64]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.